
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience is well-positioned for future success due to their strong clinical-stage assets and strategic focus on leveraging individual's neurobiology for personalized treatment options. With a solid cash runway through 2029, the company remains well-funded to continue their research and development efforts. Although delays in timing for some of their key pipeline updates may be disappointing, they do not impact the overall potential of their portfolio and current valuation of $24 per share is in line with our target.
Bears say
Alto Neuroscience is a clinical-stage biopharmaceutical company that focuses on developing personalized treatments for psychiatric disorders. However, the company carries a high level of risk due to its early stage developmental programs and unproven biomarker approach. With a low probability of success for its drug candidates and potential challenges in commercializing its products, we maintain a negative outlook on Alto Neuroscience's stock.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares